Search publications

Publications

  • García-Gerique L, Garcia-López M, Garrido- García A, Gómez-González S, Torrebadell-Burriel M, Prada-Varela E, Pascual-Pastó G, Muñoz O, Pérez-Jaume S, Lemos I, Salvador-Marcos N, Vilà-Ubach M, Doncel-Requena A, Suñol M, Carcaboso AM, Mora J and Lavarino C.

    MIF/CXCR4 signaling axis contributes to survival, invasion, and drug resistance of metastatic neuroblastoma cells in the bone marrow microenvironment.

    BMC Cancer . 22(1): 669-669.

    [doi:10.1186/s12885-022-09725-8]

  • Alcon C, Martín F, Prada-Varela E, Mora J, Soriano A, Guillén G, Gallego S, Roma J, Samitier J, Villanueva A and Montero J.

    MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment

    Cell Death Discovery . 8(1): 172-172.

    [doi:10.1038/s41420-022-00959-w]

  • Sánchez-Molina S, Figuerola-Bou E, Blanco ME, Sánchez-Jiménez M, Táboas P, Gomez-Gonzalez S, Ballaré C, García-Domínguez DJ, Prada-Varela E, Hontecillas-Prieto L, Carcaboso AM, Tirado ÓM, Hernandez-Muñoz MI, de Álava E, Lavarino C, Di Croce L and Mora J.

    RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis

    Science Advances . 6(43): 3058. Number of citations: 7

    [doi:10.1126/sciadv.aba3058]

  • Alcon C, Manzano-Muñoz A, Prada-Varela E, Mora J, Soriano A, Guillén G, Gallego S, Roma J, Samitier J, Villanueva A and Montero J.

    Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance.

    CELL DEATH & DISEASE . 11(8): 634-634. Number of citations: 10

    [doi:10.1038/s41419-020-02887-y]